NGS in Breast Cancer: Uses, Benefits & Limitations
Explore how next-generation sequencing supports hereditary breast cancer risk assessment, tumor profiling, and personalized treatment decisions.
October 24, 2026
Next-Generation Sequencing (NGS) in Breast Cancer: Applications in Precision Oncology
Next-Generation Sequencing (NGS) in Breast Cancer is transforming cancer research and precision oncology by helping clinicians identify genetic alterations that may influence disease biology, prognosis, and treatment selection. By analyzing multiple genes simultaneously, NGS can provide valuable molecular information for selected patients with breast cancer, particularly those with advanced or metastatic disease.
At PreventiGene, we aim to help individuals better understand their genetic health, navigate appropriate risk assessment, and connect with qualified healthcare professionals. Through genetic health education, risk assessment pathways, and specialist referrals, we support informed decisions about breast cancer prevention and care.
What Is Next-Generation Sequencing (NGS)?
Next-Generation Sequencing (NGS) is an advanced molecular technology that allows scientists to analyze millions of DNA fragments in parallel. Unlike traditional sequencing methods that generally examine one DNA region at a time, NGS can assess multiple genes or much larger portions of the genome within a single analysis.
In breast cancer care, NGS can help identify genetic alterations associated with tumor development, inherited cancer susceptibility, and potential responses to specific targeted therapies.
Depending on the clinical question, sequencing may focus on a selected group of genes, the protein-coding regions of the genome through whole-exome sequencing (WES), or the entire genome through whole-genome sequencing (WGS).
The appropriate method depends on the patient's clinical history, the available sample, the suspected genetic alteration, and whether the goal is to investigate inherited risk or characterize an existing tumor.
How Does NGS Help in Breast Cancer?
Breast cancer is not a single molecular disease. Tumors can differ considerably in their genetic alterations, biological behavior, and response to treatment. NGS helps investigate this molecular diversity and can contribute to more individualized clinical decisions.
1. Identifying Inherited Breast Cancer Risk
Some individuals carry inherited pathogenic variants that increase their lifetime risk of developing breast cancer. Important genes associated with hereditary breast cancer susceptibility include BRCA1, BRCA2, PALB2, CHEK2, and ATM.
Germline genetic testing typically uses a blood or saliva sample to examine DNA inherited from a person's parents. Depending on the clinical context, multigene panel testing can help identify inherited variants associated with elevated cancer risk.
A clinically significant result may influence discussions about enhanced surveillance, risk-reducing strategies, and, when relevant, testing and counseling for family members.
However, not every genetic variant increases cancer risk, and a negative result does not eliminate the possibility of developing breast cancer. Results must be interpreted alongside personal and family medical history by qualified healthcare professionals.
2. Supporting Personalized Treatment Decisions
Tumor sequencing can identify acquired genetic alterations that may help clinicians determine whether a patient could benefit from a particular targeted treatment.
Depending on the disease subtype and clinical setting, relevant biomarkers may include:
PIK3CA: Certain mutations can help establish eligibility for specific PI3K-targeted therapies in appropriate patients.
ESR1: Acquired mutations can contribute to resistance to endocrine therapy and may inform treatment selection in certain advanced breast cancers.
AKT1 and PTEN: Alterations in these genes can affect the PI3K/AKT signaling pathway and may have therapeutic implications in selected settings.
ERBB2 (HER2): Certain gene alterations may provide additional molecular information, although HER2 status for routine treatment decisions is generally established through validated protein-expression and gene-amplification tests.
NTRK gene fusions: These rare alterations may identify patients eligible for tumor-agnostic targeted therapies under applicable clinical criteria.
The presence of a genetic alteration does not automatically mean that a targeted treatment will work. Treatment eligibility depends on the exact alteration, the cancer subtype, previous treatments, regulatory approvals, and current clinical guidelines.
3. Understanding Tumor Heterogeneity and Treatment Resistance
Cancer cells can acquire additional genetic alterations as a tumor grows or responds to treatment. As a result, a tumor's molecular profile may change over time, and different tumor sites may contain different genetic alterations.
NGS can help researchers and clinicians investigate this heterogeneity and identify potentially actionable changes. In selected patients with advanced breast cancer, molecular profiling may support treatment planning when standard treatment options have become less effective.
When clinically appropriate, sequencing can be performed on tumor tissue or, for certain biomarkers, circulating tumor DNA (ctDNA) obtained from a blood sample.
A blood-based ctDNA test may provide useful molecular information without requiring a new tissue biopsy. However, it cannot detect every tumor alteration. A negative blood result may therefore require follow-up testing of tumor tissue when clinically indicated.
How Is NGS Performed in Breast Cancer?
The sequencing workflow varies according to the test, laboratory, sample type, and clinical purpose. A typical tumor-profiling workflow includes the following steps.
Step 1: Selecting the Appropriate Sample
For tumor profiling, a laboratory may use tissue obtained from a biopsy or surgery. For selected applications, a blood sample can be used to analyze circulating tumor DNA.
For inherited cancer-risk testing, a blood or saliva sample is commonly used to examine germline DNA.
These sample types are not interchangeable: tumor testing and germline testing answer different clinical questions.
Step 2: DNA Extraction and Quality Assessment
DNA is extracted from the selected sample and assessed for quantity and quality. Adequate sample quality is essential for reliable sequencing, although the required amount of DNA depends on the assay.
Step 3: Library Preparation and Sequencing
The DNA is prepared for sequencing using a validated laboratory protocol. Depending on the assay, selected genes or broader genomic regions are analyzed to identify relevant genetic variants.
Step 4: Bioinformatics Analysis
Specialized computational tools process sequencing data, identify potential variants, and compare findings with appropriate reference sequences and databases.
Quality control is essential because sequencing errors, low coverage, and limitations in detecting certain variant types can affect interpretation.
Step 5: Clinical Interpretation and Reporting
A qualified laboratory team interprets the findings and prepares a report. Variants are classified according to established criteria, and potentially actionable alterations are evaluated in the context of current evidence.
The final report should be reviewed by the treating clinician, who can determine whether additional testing, genetic counseling, surveillance, or a change in treatment is appropriate.
NGS vs. Traditional Genetic Testing in Breast Cancer
NGS and conventional molecular tests serve complementary purposes. NGS can examine multiple genes simultaneously, while targeted methods may be more appropriate for specific clinical questions.
For example, BRCA1 and BRCA2 testing can be performed using NGS or other validated methods. Similarly, HER2 status is usually determined through immunohistochemistry (IHC) and, when indicated, in situ hybridization (ISH), rather than relying on NGS alone.
Therefore, NGS should not be considered a universal replacement for established breast cancer diagnostic methods.
NGS and Liquid Biopsy: What Is the Difference?
Liquid biopsy refers to the analysis of cancer-associated material obtained from body fluids, most commonly blood. One important target is circulating tumor DNA (ctDNA), which consists of DNA fragments released into the bloodstream by tumor cells.
NGS is one of the technologies that can be used to analyze ctDNA and identify selected genetic alterations.
In advanced breast cancer, ctDNA-based genomic profiling may help detect actionable mutations, assess molecular changes, or inform treatment decisions when an appropriate validated test is available.
Nevertheless, liquid biopsy has limitations. Small tumors or tumors that release very little DNA into the bloodstream may not produce detectable ctDNA. A negative result does not necessarily mean that a tumor lacks a particular genetic alteration.
Importantly, neither NGS nor ctDNA analysis should be presented as a stand-alone screening test for breast cancer in asymptomatic individuals. Routine screening recommendations continue to rely on established approaches, including mammography when appropriate for an individual's age and risk profile.
Benefits and Limitations of NGS in Breast Cancer
Key Benefits
Broad genetic analysis: Multiple genes can be assessed in a single test.
Personalized treatment support: Certain findings may help identify patients eligible for targeted therapies.
Hereditary risk assessment: Germline testing can identify inherited variants associated with elevated breast cancer risk.
Research advancement: NGS helps researchers investigate tumor biology, treatment resistance, and molecular differences between patients.
Potential for repeat molecular assessment: Selected blood-based tests can provide additional information about tumor genetics during advanced disease management.
Important Limitations
Not every alteration is actionable: Many detected variants have no established treatment implication.
Variants of uncertain significance: Some findings cannot yet be classified as benign or disease-causing.
False-negative or inconclusive results: Sample quality, low tumor DNA levels, and assay limitations can affect detection.
Interpretation requires expertise: Results must be considered alongside clinical findings and established treatment guidelines.
Cost and accessibility: Comprehensive sequencing may not be available or appropriate for every patient.
Privacy and inherited implications: Germline testing can reveal information relevant to biological relatives and requires appropriate consent and counseling.
The Role of PreventiGene in Breast Cancer Risk Assessment
Understanding breast cancer risk involves more than a single genetic test. Personal medical history, family history, age, established risk factors, and appropriate clinical screening all contribute to a comprehensive assessment.
PreventiGene supports this process through genetic health education, online risk-assessment pathways, and referral to qualified healthcare professionals when further evaluation is appropriate.
Our approach is designed to help individuals understand when discussing hereditary cancer risk or additional testing with a healthcare professional may be worthwhile.
The process may include:
Initial risk assessment: Individuals provide relevant information through an appropriate health-risk questionnaire.
Review of potential risk factors: Personal and family history may indicate whether further clinical evaluation is warranted.
Specialist referral: When appropriate, individuals can be directed to a qualified healthcare professional for further assessment, genetic counseling, or discussion of testing options.
Informed next steps: Healthcare professionals can explain suitable screening, validated genetic tests, and follow-up options based on the individual's circumstances.
NGS or other genetic testing should only be recommended when clinically appropriate. PreventiGene's online assessment is not a diagnostic test, and it cannot independently confirm or exclude breast cancer or an inherited cancer-predisposition syndrome.
Any future testing services must be evaluated according to their intended use, analytical and clinical validation, and applicable regulatory requirements.
The Future of NGS in Breast Cancer Research
Advances in sequencing technology are expanding our understanding of breast cancer at multiple biological levels. Emerging approaches include single-cell RNA sequencing, spatial transcriptomics, and increasingly sensitive analysis of circulating tumor DNA.
Single-cell sequencing can help researchers investigate differences between individual cells within a tumor, while spatial transcriptomics can reveal how gene activity varies across different tissue regions. These approaches may improve understanding of tumor heterogeneity, immune interactions, and mechanisms of treatment resistance.
Although these technologies hold considerable research promise, many applications remain investigational or are limited to specific clinical settings. Their routine use depends on further validation and evidence that the results improve patient management.
Conclusion
Next-Generation Sequencing is an important tool in modern breast cancer research and selected areas of clinical care. It can help identify inherited cancer-predisposition variants, characterize tumor-associated genetic alterations, and support treatment decisions when validated biomarkers have established clinical relevance.
However, NGS is not a replacement for mammography, breast imaging, biopsy, pathology, or professional medical evaluation. Its value depends on choosing the correct test, obtaining an appropriate sample, and interpreting the findings within the patient's clinical context.
At PreventiGene, we aim to make genetic health information more understandable and help individuals navigate appropriate risk assessment and specialist referral. By connecting education with evidence-based healthcare pathways, we support more informed conversations about breast cancer risk, genetic testing, and personalized care.
Medical disclaimer: This article is intended for educational purposes only and does not replace professional medical advice, diagnosis, genetic counseling, or treatment recommendations.
Frequently Asked Questions (FAQs)
What is NGS testing for breast cancer?
NGS is a sequencing technology that analyzes multiple DNA regions simultaneously. In selected breast cancer settings, it can identify inherited or tumor-acquired genetic alterations that may inform risk assessment or treatment decisions.
Can NGS detect hereditary breast cancer?
Yes. NGS-based germline testing can identify pathogenic variants in genes associated with inherited breast cancer susceptibility, including BRCA1, BRCA2, and PALB2. The test should be selected and interpreted according to clinical guidelines and personal and family history.
Can NGS determine which breast cancer treatment will work?
NGS may identify biomarkers associated with eligibility for certain targeted therapies. However, it cannot guarantee treatment response, and the findings must be interpreted alongside the cancer subtype, clinical history, and available evidence.
Is NGS the same as a liquid biopsy?
No. Liquid biopsy describes a method of analyzing material from a body fluid. NGS is a sequencing technology that may be used to analyze circulating tumor DNA obtained through a liquid biopsy.
Can NGS replace mammography for breast cancer screening?
No. NGS is not a substitute for established breast cancer screening. Mammography and other recommended screening or diagnostic procedures remain important, with the appropriate approach determined by age, risk factors, and clinical guidance.
Should everyone undergo NGS testing for breast cancer?
No. The most appropriate test depends on whether the goal is to assess inherited risk, investigate an existing tumor, or identify a treatment-related biomarker. A qualified healthcare professional can help determine whether testing is indicated.
